Search

This study observed the effects of edaravone combined with Dl-3-N-butylphthalide (NBP) on the serum levels of tumor necrosis factor-alpha (TNF-β), interleukin-10 (IL-10), and neuron-specific enolase (NSE), and its therapeutic effect in patients with acute cerebral infarction (ACI). The purpose of this study was to explore whether edaravone combined with NBP could improve the neurological function of patients with ACI. A total of 86 patients with ACI were enrolled in this study; 43 patients were randomly assigned to the control group and treated with edaravone only, while the other 43 patients were assigned to the intervention group and treated with a combination of edaravone and NBP. The course of treatment lasted 14 days, and the basic drug treatment was the same in both groups. The effective rate of activity of daily living scores (ADL) was significantly higher in the intervention than in the control group, and the difference was statistically significant (P<0.05). After the treatment had been administered, the National Institute of Health Stroke Scale scores of the two groups were lower than before the treatment, and the scores were lower in the intervention compared with the control group; the difference was statistically significant (P<0.05). After the treatment had been administered, the serum levels of TNF-β and NSE were significantly lower in the intervention than in the control group, and the serum IL-10 level was significantly higher in the intervention than in the control group; the differences were statistically significant (P<0.05). Edaravone combined with NBP improved the neurological function of patients with ACI, improved their quality of life, significantly decreased the serum levels of TNF-β and NSE, increased the serum IL-10 level, and had a better effect. This combination therapy method can be adopted in clinics to treat patients with ACI. [ABSTRACT FROM AUTHOR]